<DOC>
	<DOCNO>NCT00931645</DOCNO>
	<brief_summary>Phase III trial evaluate role autologous stem cell transplantation previously untreated patient 65 year stage B C B-cell chronic lymphocytic leukemia . Endpoints trial : - major : progression free survival 3 year - secondary : overall survival , tolerance , prognostic factor accord baseline clinical stage biological characteristic ( IgHv mutational status , expression ZAP70 CD38 , cytogenetics ) .</brief_summary>
	<brief_title>Autologous Stem Cell Transplantation Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>All register patient treat 6 monthly course chemotherapy . First three one CHOP regimen half dosage adriamycin , previously publish ( Effectiveness `` CHOP '' regimen advance untreated chronic lymphocytic leukemia . French Cooperative Group Chronic Lymphocytic Leukemia . Lancet ; 1986 , : 1346-1349 ) , follow three subsequent course IV fludarabine ( 25 mg/sqm d1-5 ) . Patients CR ( NCI , 1996 , include CAT scan evaluation ) randomize surveillance without additional treatment autologous stem cell transplantation use peripheral stem cell collect three first course chemotherapy , and/or completion six course necessary . For patient CR six course , rescue regimen DHAP association ( cisplatin , 100 mg/sqm d1 , cytarabine 2 g/sqm d2 , dexamethasone 40 mg/sqm d1-4 ) precede additional stem cell collection necessary , patient randomize autologous stem cell transplantation three additional course association fludarabine ( 25 mg/sqm d1-3 ) cyclophosphamide ( 300 mg/sqm d1-3 ) . Conditioning regimen associate TBI ( 10 gray , -3-1 ) cyclophosphamide ( 60 mg/sqm d-5-4 ) . Evaluation response wil perform randomisation two month completion therapy arm . Follow-up data register monitored every three month first year , every six month . Criteria evaluation response use NCI system ( 1996 ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>patient stage B &amp; C CLL , 18 65 year . previously untreated give write informed consent Childbearing woman OMS Performance status &gt; 2 Binet stage A Autoimmune hemolytic anemia Active previous ( &lt; 5 year ) malignant disease , except cutaneous cell carcinoma . Previous CLL treatment HIV seropositivity Abnormal renal liver function test ( creatinine &gt; 1,5N , transaminase &gt; 2N , bilirubin &gt; 1,5N ) Cardiac failure ( ejection fraction &lt; 50 % ) Lung disease perturb ventilation test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Chronic lymphocytic leukemia ,</keyword>
	<keyword>autologous stem cell transplantation</keyword>
</DOC>